TAVO412 had stronger tumor growth inhibition than amivantamab and cetuximab, since the design had more engineered MOA that included: angiogenesis control by the anti-VEGF arm; enhanced ADCC, ADCP, and CDC mediated by the unique dual-epitope EGFR and cMET binding epitopes. The gene discussed is EGFR; the disease is neoplasm.